- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04284839
De directe orale antistolling versus warfarine na hartchirurgie (DANCE)
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Approximately 36,000 Canadian adults undergo cardiac surgery annually. Of these patients, about 10% have a prior history of atrial fibrillation (AF). In the early post-operative period after cardiac surgery, 30-60% of patients develop AF and, by the time of discharge, 32% of patients who underwent cardiac surgery have an indication for oral anticoagulation (OAC). AF is associated with a significantly higher risk of stroke, even when transient, and OAC is the standard for thromboembolic prevention in these patients. In the post-operative period, the balance of benefits and risks of OAC may differ and the safest and most effective OAC in that patient population is uncertain.
Vitamin K antagonists (VKAs), such as warfarin or coumadin, are the most used anticoagulants after cardiac surgery. In the Left Atrial Appendage Occlusion Study (LAAOS) III that recruited 4811 patients from 105 centres in 27 countries, 77% of patients with AF on OAC were discharged on a VKA after cardiac surgery. Among patients taking a DOAC preoperatively, 55% were switched to a VKA after surgery. Over the first post-operative year, most of those patients were gradually transitioned back to a DOAC. Although effective, the use of VKAs is limited by a narrow therapeutic index requiring frequent international normalized ratio (INR) measurements to ensure appropriate levels of anticoagulation. This key limitation leads to non-compliance and discontinuation. In addition, in the first 3 months after cardiac surgery, time in the therapeutic range is low, even with close monitoring by experienced prescribers.
In the last decade, DOACs - inhibitors of factor Xa or thrombin- have become broadly used in patients with AF. Treatment with a DOAC in patients with AF has been demonstrated to yield a lower risk of stroke or systemic embolism and a similar risk of major bleeding when compared to VKAs during long-term follow-up. Moreover, DOACs are more convenient for both patients and clinicians. They have a rapid onset of effect, fixed dosage that obviates the need for regular monitoring, and few interactions with food and other medications. In the postoperative setting, DOACs may also lead to shorter length of stay and reduced costs.
The purpose of this study is to establish whether DOACs are as safe as VKAs in the first few weeks after heart surgery. The results of this study will impact the treatment of hundreds of thousands of patients in the world every year.
A subset of 910 DANCE participants with a recent bioprosthetic aortic and/or mitral valve replacement will be enrolled in the SUNDANCE substudy (Subclinical valve thrombosis in patients with surgical bioprosthetic valve replacement: An imaging substudy of the DANCE trial). SUNDANCE will examine the effects of DOACs versus VKAs on subclinical valve thrombosis and bioprosthetic valve function by conducting computed tomography (CT) scans and echocardiograms at 60 to 90 days after randomization.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Richard Whitlock, MD, PhD
- Telefoonnummer: 40306 905-527-4322
- E-mail: richard.whitlock@phri.ca
Studie Contact Back-up
- Naam: Emilie Belley-Cote, MD, MSc
- Telefoonnummer: 40306 905-527-4322
- E-mail: emilie.belley-cote@phri.ca
Studie Locaties
-
-
Victoria
-
Fitzroy, Victoria, Australië, 3065
- Werving
- St Vincent's Hospital Melbourne
-
Contact:
- Andrew Newcomb, MD
-
Hoofdonderzoeker:
- Andrew Newcomb, MD
-
Parkville, Victoria, Australië, 3050
- Nog niet aan het werven
- Royal Melbourne Hospital, University of Melbourne
-
Contact:
- Alistair Royse, MD
-
Hoofdonderzoeker:
- Alistair Royse, MD
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2C8
- Werving
- University of Alberta Hospital
-
Hoofdonderzoeker:
- Steven Meyer, MD
-
Contact:
- Steven Meyer, MD
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z3
- Werving
- University of British Columbia
-
Hoofdonderzoeker:
- Erica Wang, PharmD
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- Werving
- St. Boniface Hospital
-
Hoofdonderzoeker:
- Michael Yamashita, MD
-
Contact:
- Michael Yamashita, MD
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L4L2
- Actief, niet wervend
- Saint John Regional Hospital
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Werving
- Health Science Centre
-
Hoofdonderzoeker:
- Hasib Hanif, MD
-
-
Ontario
-
Greater Sudbury, Ontario, Canada, P3E 5J1
- Werving
- Health Sciences North Research Institute
-
Hoofdonderzoeker:
- Bindu Bittira, MD
-
Hamilton, Ontario, Canada, L8L 2X2
- Werving
- Hamilton General Hospital
-
Contact:
- Emilie Belley-Cote, MD, MSc
- Telefoonnummer: 40306 905-527-4322
- E-mail: emilie.belley-cote@phri.ca
-
Toronto, Ontario, Canada, M5G 2C4
- Werving
- Toronto General Hospital
-
Contact:
- Vivek Rao, MD
-
Hoofdonderzoeker:
- Vivek Rao, MD
-
Toronto, Ontario, Canada, M4N 3M5
- Werving
- Sunnybrook Hospital
-
Contact:
- Stephen Fremes, MD
-
Hoofdonderzoeker:
- Stephen Fremes, MD
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Werving
- Montreal Heart Institute
-
Contact:
- Philippe Demers, MD
-
Hoofdonderzoeker:
- Philippe Demers, MD
-
Montreal, Quebec, Canada, H4J1C5
- Werving
- Hôpital Sacré-Coeur de Montréal
-
Hoofdonderzoeker:
- Hugues Jeanmart, MD
-
Contact:
- Hugues Jeanmart, MD
-
Québec, Quebec, Canada, G1V 4G5
- Werving
- IUCPQ-ULaval
-
Contact:
- Eric Dumont, MD
-
Hoofdonderzoeker:
- Eric Dumont, MD
-
-
-
-
-
Bonn, Duitsland, 53127
- Actief, niet wervend
- University Hospital Bonn Heart Center
-
Essen, Duitsland, 45147
- Nog niet aan het werven
- West-German Heart and Vascular Center, University of Duisburg-Essen
-
Contact:
- Matthias Thielmann, MD, PhD
-
Hoofdonderzoeker:
- Matthias Thielmann, MD, PhD
-
Hamburg, Duitsland, 20246
- Werving
- University Medical Center Hamburg-Eppendorf
-
Contact:
- Simon Pecha, MD
-
Hoofdonderzoeker:
- Simon Pecha, MD
-
-
Saxony
-
Leipzig, Saxony, Duitsland, 04289
- Actief, niet wervend
- Heart Center Leipzig
-
-
Thuringia
-
Jena, Thuringia, Duitsland, Germany
- Werving
- University Hospital Jena
-
Contact:
- Torsten Doenst, MD, PhD
-
Hoofdonderzoeker:
- Torsten Doenst, MD, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥18 years at the time of enrolment,
- Open heart surgery in the last 10 days,
- Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),
- Informed consent from either the patient or a substitute decision-maker.
Exclusion Criteria:
- Mechanical valve replacement,
- Antiphospholipid syndrome (triple positive),
- Severe renal failure (Cockcroft-Gault equation; creatinine clearance <15 ml/min),
- Known significant liver disease (Child-Pugh classification B and C),
- Left ventricular thrombus,
- Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
- Known contraindication for any DOAC or VKA,
- Women who are pregnant, breastfeeding, or of childbearing potential,
- Surgery including left ventricular assist device implantation or cardiac transplantation,
- Previously enrolled in this trial,
- Follow-up not possible,
- History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Faculteitstoewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Direct Oral Anticoagulation (DOAC)
Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician. |
Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
Andere namen:
|
|
Placebo-vergelijker: Vitamin K Antagonist
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range. |
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Major Bleeding
Tijdsspanne: 30-Days post-randomization
|
Major bleeding at 30 days, defined as bleeding that results in death and/or symptomatic bleeding in a critical area or organ, bleeding into a surgical site requiring reoperation, bleeding leading to hospitalization (including presentation to an acute care facility without overnight stay) and/or bleeding that causes a drop in the hemoglobin level of 20g/L or more or that which requires the transfusion of ≥2 units of packed red blood cells or whole blood (as defined by the International Society of Thrombosis and Hemostasis) |
30-Days post-randomization
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Samenstelling van beroerte en systemische arteriële embolie van niet-centraal zenuwstelsel na 30 en 90 dagen.
Tijdsspanne: 30 dagen en 90 dagen na randomisatie
|
30 dagen en 90 dagen na randomisatie
|
|
Grote bloeding
Tijdsspanne: 90 dagen na randomisatie
|
90 dagen na randomisatie
|
|
Pleurale of pericardiale effusie die drainage vereist
Tijdsspanne: 30 dagen en 90 dagen na randomisatie
|
30 dagen en 90 dagen na randomisatie
|
|
Systemische arteriële embolie
Tijdsspanne: 30 dagen en 90 dagen na randomisatie
|
30 dagen en 90 dagen na randomisatie
|
|
Ischemische beroerte
Tijdsspanne: 30 dagen en 90 dagen na randomisatie
|
30 dagen en 90 dagen na randomisatie
|
|
Diepe veneuze trombose
Tijdsspanne: 30 dagen en 90 dagen na randomisatie
|
30 dagen en 90 dagen na randomisatie
|
|
Longembolie
Tijdsspanne: 30 dagen en 90 dagen na randomisatie
|
30 dagen en 90 dagen na randomisatie
|
|
Duur van het postoperatieve ziekenhuisverblijf
Tijdsspanne: 30 dagen en 90 dagen na randomisatie
|
30 dagen en 90 dagen na randomisatie
|
|
Sterfte door alle oorzaken
Tijdsspanne: 6 maanden na randomisatie
|
6 maanden na randomisatie
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Myocardinfarct
Tijdsspanne: 30 dagen en 90 dagen na randomisatie
|
30 dagen en 90 dagen na randomisatie
|
|
|
Associatie tussen subklinische kleptrombose en klinisch significante aortakleptrombose, beroerte of systemische embolie
Tijdsspanne: 90 dagen
|
90 dagen
|
|
|
Minor Bleeding
Tijdsspanne: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All bleeding (major plus minor)
Tijdsspanne: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Valve Thrombosis
Tijdsspanne: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Hemorrhagic stroke
Tijdsspanne: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Stroke
Tijdsspanne: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Arterial Thrombosis/thromboembolism
Tijdsspanne: 30-Days and 90-Days post-randomization
|
Tertiary outcome: ischemic stroke, systemic arterial embolism, myocardial infarction, valve thrombosis |
30-Days and 90-Days post-randomization
|
|
Quality of Life - EQ-5D-5L
Tijdsspanne: 30-Days and 90-Days post-randomization
|
Tertiary outcome: Measured by The EQ-5D-5L Questionnaire |
30-Days and 90-Days post-randomization
|
|
Patient Satisfaction with Anticoagulant treatment
Tijdsspanne: 30-Days and 90-Days post-randomization
|
Tertiary outcome: Assessed by the Perception of Anticoagulant Treatment Questionnaire |
30-Days and 90-Days post-randomization
|
|
Subclinical Valve Thrombosis on CT scan
Tijdsspanne: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Mean Aortic Valve g=Gradient on echocardiogram
Tijdsspanne: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Aortic Valve Reintervention
Tijdsspanne: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Emilie Belley-Cote, MD, MSc, McMaster University
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Pathologische aandoeningen, tekenen en symptomen
- Bloeding
- Zwavelverbindingen
- Organische chemicaliën
- Pyridines
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Benzimidazolen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Pyrans
- Morfolines
- Oxazines
- Thiophenes
- Coumarins
- Benzopyrans
- 4-hydroxycoumarins
- Rivaroxaban
- Dabigatran
- Warfarine
- Apixaban
- Edoxaban
Andere studie-ID-nummers
- DANCE-2020
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
We will establish a plan for the full-scale study but there is no plan to make IPD available to other researchers.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .